Inhibikase Therapeutics Inc Sustainability Reports
Inhibikase Therapeutics Inc. is a clinical-stage pharmaceutical company focused on developing protein kinase inhibitor therapeutics. The company primarily develops therapies to modify the course of cardiopulmonary diseases such as Pulmonary Arterial Hypertension (PAH).
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300066CFEWOA17F12
FIGI: BBG005TP2348
2 reports from 2023 to 2024
